Tonix Pharmaceuticals (NASDAQ:TNXP) Stock Price Down 11.1% – What’s Next?

Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP)’s stock price fell 11.1% during trading on Thursday . The stock traded as low as $0.26 and last traded at $0.26. 72,709,392 shares changed hands during trading, a decline of 5% from the average session volume of 76,777,180 shares. The stock had previously closed at $0.29.

Wall Street Analysts Forecast Growth

Separately, StockNews.com began coverage on Tonix Pharmaceuticals in a research report on Thursday. They set a “hold” rating for the company.

Tonix Pharmaceuticals Stock Performance

The stock has a market cap of $52.09 million, a PE ratio of -0.01 and a beta of 2.02. The stock has a 50-day moving average of $0.25 and a 200 day moving average of $0.33. The company has a quick ratio of 2.81, a current ratio of 3.33 and a debt-to-equity ratio of 0.07.

Tonix Pharmaceuticals (NASDAQ:TNXP) last announced its quarterly earnings data on Tuesday, November 12th. The company reported ($0.23) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($2.03) by $1.80. The firm had revenue of $2.82 million during the quarter, compared to analyst estimates of $2.63 million. Tonix Pharmaceuticals had a negative net margin of 1,197.86% and a negative return on equity of 163.95%. Equities analysts predict that Tonix Pharmaceuticals Holding Corp. will post -17.63 EPS for the current fiscal year.

Tonix Pharmaceuticals Company Profile

Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults.